These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

914 related items for PubMed ID: 24039206

  • 1. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
    Zimmermann AK, Camenisch U, Rechsteiner MP, Bode-Lesniewska B, Rössle M.
    Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206
    [Abstract] [Full Text] [Related]

  • 2. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X, Luo Y, Bai Q, Lu Y, Lu Y, Wu L, Zhou X.
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [Abstract] [Full Text] [Related]

  • 3. Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma.
    Wobker SE, Kim LT, Hackman TG, Dodd LG.
    Cancer Cytopathol; 2015 Sep; 123(9):531-9. PubMed ID: 26080065
    [Abstract] [Full Text] [Related]

  • 4. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
    Ilie MI, Lassalle S, Long-Mira E, Bonnetaud C, Bordone O, Lespinet V, Lamy A, Sabourin JC, Haudebourg J, Butori C, Guevara N, Peyrottes I, Sadoul JL, Bozec A, Santini J, Capper D, von Deimling A, Emile JF, Hofman V, Hofman P.
    Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
    [Abstract] [Full Text] [Related]

  • 5. Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens.
    Meng Z, Lu J, Wu H, Zhao Y, Luo Y, Gao J, Zhu Q, Jiang Y, Li W, Liang Z.
    Tumour Biol; 2016 Jan; 37(1):611-8. PubMed ID: 26240026
    [Abstract] [Full Text] [Related]

  • 6. Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
    Crescenzi A, Guidobaldi L, Nasrollah N, Taccogna S, Cicciarella Modica DD, Turrini L, Nigri G, Romanelli F, Valabrega S, Giovanella L, Onetti Muda A, Trimboli P.
    Horm Metab Res; 2014 May; 46(5):370-4. PubMed ID: 24570209
    [Abstract] [Full Text] [Related]

  • 7. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.
    Paek SH, Kim BS, Kang KH, Kim HS.
    World J Surg Oncol; 2017 Nov 13; 15(1):202. PubMed ID: 29132392
    [Abstract] [Full Text] [Related]

  • 8. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.
    Zhao H, Zhang ZH, Zhou B, Xiao T, Pan QJ, Guo HQ.
    Diagn Cytopathol; 2015 Oct 13; 43(10):786-90. PubMed ID: 26152656
    [Abstract] [Full Text] [Related]

  • 9. Utility of BRAF mutation detection in fine-needle aspiration biopsy samples read as "suspicious for papillary thyroid carcinoma".
    Jara SM, Bhatnagar R, Guan H, Gocke CD, Ali SZ, Tufano RP.
    Head Neck; 2015 Dec 13; 37(12):1788-93. PubMed ID: 24989827
    [Abstract] [Full Text] [Related]

  • 10. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area.
    Lee ST, Kim SW, Ki CS, Jang JH, Shin JH, Oh YL, Kim JW, Chung JH.
    J Clin Endocrinol Metab; 2012 Jul 13; 97(7):2299-306. PubMed ID: 22500044
    [Abstract] [Full Text] [Related]

  • 11. BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: impact on diagnosis and prognosis.
    Colanta A, Lin O, Tafe L, Ghossein R, Nafa K, Mitchell T, Ladanyi M, Arcila M.
    Acta Cytol; 2011 Jul 13; 55(6):563-9. PubMed ID: 22156467
    [Abstract] [Full Text] [Related]

  • 12. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing.
    Estrella JS, Tetzlaff MT, Bassett RL, Patel KP, Williams MD, Curry JL, Rashid A, Hamilton SR, Broaddus RR.
    Mol Cancer Ther; 2015 Dec 13; 14(12):2887-95. PubMed ID: 26438153
    [Abstract] [Full Text] [Related]

  • 13. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area.
    Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, Park DJ, Lee HS, Cho BY, Lee ES, Kim SW.
    Clin Endocrinol (Oxf); 2006 Nov 13; 65(5):660-6. PubMed ID: 17054470
    [Abstract] [Full Text] [Related]

  • 14. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.
    Sun J, Zhang J, Lu J, Gao J, Lu T, Ren X, Duan H, Liang Z.
    Int J Clin Exp Pathol; 2015 Nov 13; 8(11):15072-8. PubMed ID: 26823846
    [Abstract] [Full Text] [Related]

  • 15. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAFV600E Mutation in Papillary Thyroid Carcinoma.
    Kim JK, Seong CY, Bae IE, Yi JW, Yu HW, Kim SJ, Won JK, Chai YJ, Choi JY, Lee KE.
    Ann Surg Oncol; 2018 Jun 13; 25(6):1775-1781. PubMed ID: 29611028
    [Abstract] [Full Text] [Related]

  • 16. Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma.
    Bullock M, O'Neill C, Chou A, Clarkson A, Dodds T, Toon C, Sywak M, Sidhu SB, Delbridge LW, Robinson BG, Learoyd DL, Capper D, von Deimling A, Clifton-Bligh RJ, Gill AJ.
    Endocr Relat Cancer; 2012 Dec 13; 19(6):779-84. PubMed ID: 22997209
    [Abstract] [Full Text] [Related]

  • 17. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.
    Pizzolanti G, Russo L, Richiusa P, Bronte V, Nuara RB, Rodolico V, Amato MC, Smeraldi L, Sisto PS, Nucera M, Bommarito A, Citarrella R, Lo Coco R, Cabibi D, Lo Coco A, Frasca F, Gulotta G, Latteri MA, Modica G, Galluzzo A, Giordano C.
    Thyroid; 2007 Nov 13; 17(11):1109-15. PubMed ID: 17727338
    [Abstract] [Full Text] [Related]

  • 18. BRAF p.Val600Glu (V600E) mutation detection in thyroid fine needle aspiration cell block samples: a feasibility study.
    Leslie C, Grieu-Iacopetta F, Richter A, Platten M, Murray J, Frost FA, Amanuel B, Kumarasinghe MP.
    Pathology; 2015 Aug 13; 47(5):432-8. PubMed ID: 26154146
    [Abstract] [Full Text] [Related]

  • 19. The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology.
    Straccia P, Brunelli C, Rossi ED, Lanza P, Martini M, Musarra T, Lombardi CP, Pontecorvi A, Fadda G.
    Cytopathology; 2019 Sep 13; 30(5):460-467. PubMed ID: 30875124
    [Abstract] [Full Text] [Related]

  • 20. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies.
    Zatelli MC, Trasforini G, Leoni S, Frigato G, Buratto M, Tagliati F, Rossi R, Cavazzini L, Roti E, degli Uberti EC.
    Eur J Endocrinol; 2009 Sep 13; 161(3):467-73. PubMed ID: 19574281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.